# Cetuximab

## Erbitux inj 100mg/20mL

##### 臨採

| TAH Drug Code      | [IERB2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IERB2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for the treatment of metastatic colorectal cancer (CRC) in patients with RAS wild-type. - First-line treatment in combination with FOLFIRI (Folinic acid/5-FU/Irinotecan). - First-line treatment in combination with FOLFOX. In combination with encorafenib for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC) harboring a BRAF V600E mutation. In combination with radiation therapy for the treatment of patients with locally advanced oropharyngeal, hypopharyngeal, and laryngeal cancer. In combination with platinum-based chemotherapy for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. |
| Dosing             | Weekly dosing: Initial loading dose: 400 mg/m2 infused over 120 minutes. Maintenance dose: 250 mg/m2 infused over 60 minutes once weekly until disease progression or unacceptable toxicity. Complete cetuximab dose 1 hour prior to chemotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Known severe hypersensitivity reactions to cetuximab.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Adverse Effects    | Mild or moderate infusion-related reactions eg fever, chills, dizziness or dyspnea; mild to moderate mucositis, increase in liver enzyme levels; skin reactions mainly as acne-like rash; headache; conjunctivitis; diarrhea, nausea, vomiting; dehydration, hypocalcemia, anorexia; fatigue.                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – No Relevant Animal Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/cetuximab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

